source
- Genmab's bispecific combo with Keytruda halves death risk in phase 3 head‑neck cancer trialGenmab announced interim results from its phase 3 LiGeR-HN1 study, showing that adding the bispecific antibody petosemtamab to Merck's Keytruda significantly improved outcomes for patients with PD-…
- Lilly's retatrutide outperforms Ozempic in phase 3 trial, cutting blood sugar and weight moreEli Lilly tested its triple-G candidate retatrutide against Novo Nordisk's Ozempic (semaglutide) in an open-label phase 3 study involving about 1,300 adults with type 2 diabetes whose glucose was n…